Mechanistic insights into antitumor effects of new dinuclear cis PtII complexes containing aromatic linkers

Biochemical Pharmacology

Volumn 80, Issue 3, 2010, Pages 344-351

  Zerzankova, Lenka ^a   Kostrhunova, Hana ^a   Vojtiskova, Marie ^a   Novakova, Olga ^a   Suchankova, Tereza ^b   Lin, Miaoxin ^c   Guo, Zijian ^c   Kasparkova, Jana ^a   Brabec, Viktor ^a  

^a INSTITUTE OF BIOPHYSICS   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

^c NANJING UNIVERSITY   (China)

Author keywords

Antitumor; Dinuclear platinum; DNA damage; Interstrand cross link; Recognition

Indexed keywords

CIS PLATINUM DIAMINODICHLORIDE(4,4' METHYLENEDIANILINE); CIS PLATINUM DIAMINODICHLORIDE(ALPHA,ALPHA' DIAMINO PARA XYLENE); CISPLATIN; DNA; PLATINUM COMPLEX; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DNA CROSS LINKING; DNA MODIFICATION; DRUG DNA INTERACTION; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; CROSS-LINKING REAGENTS; DNA ADDUCTS; DNA DAMAGE; HELA CELLS; HUMANS;

EID: 77953364366     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.04.013     Document Type: Article

References (54)

1. Pratesi G., Perego P., Polizzi D., Righetti S.C., Supino R., Caserini C., et al. A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts. Br J Cancer 1999, 80:1912-1919.
2. Farrell N. Polynuclear platinum drugs. Metal ions in biological systems 2004, 251-296. Marcel Dekker, Inc., New York and Basel. A. Sigel, H. Sigel (Eds.).
3. Brabec V., Kasparkova J. Modifications of DNA by platinum complexes: relation to resistance of tumors to platinum antitumor drugs. Drug Resist Updat 2005, 8:131-146.
4. Brabec V., Kasparkova J. DNA interactions of platinum anticancer drugs: recent advances and mechanisms of action. Metal compounds in cancer chemotherapy 2005, 187-218. Research Signpost, Trivandrum, Kerala (India). J.-M. Perez-Martin, M.A. Fuertes, C. Alonso (Eds.).
5. 2(piperazine)]. Biochem Pharmacol 2007, 73:1887-1900.
6. Cossa G., Gatti L., Zunino F., Perego P. Strategies to improve the efficacy of platinum compounds. Curr Med Chem 2009, 16:2355-2365.
7. Kasparkova J., Farrell N., Brabec V. Sequence specificity, conformation, and recognition by HMG1 protein of major DNA interstrand cross-links of antitumor dinuclear platinum complexes. J Biol Chem 2000, 275:15789-15798.
8. Kasparkova J., Zehnulova J., Farrell N., Brabec V. DNA interstrand cross-links of the novel antitumor trinuclear platinum complex BBR3464: conformation, recognition by high mobility group domain proteins, and nucleotide excision repair. J Biol Chem 2002, 277:48076-48086.
9. Brabec V., Kasparkova J., Vrana O., Novakova O., Cox J.W., Qu Y., et al. DNA modifications by a novel bifunctional trinuclear platinum Phase I anticancer agent. Biochemistry 1999, 38:6781-6790.
10. Kasparkova J., Novakova O., Vrana O., Farrell N., Brabec V. Effect of geometric isomerism in dinuclear platinum antitumor complexes on DNA interstrand cross-linking. Biochemistry 1999, 38:10997-11005.
11. Zehnulova J., Kasparkova J., Farrell N., Brabec V. Conformation, recognition by high mobility group domain proteins, and nucleotide excision repair of DNA intrastrand cross-links of novel antitumor trinuclear platinum complex BBR3464. J Biol Chem 2001, 276:22191-22199.
12. Roberts J.D., Peroutka J., Farrell N. Cellular pharmacology of polynuclear platinum anti-cancer agents. J Inorg Biochem 1999, 77:51-57.
13. Roberts J.D., Beggiolin G., Manzotti C., Piazzoni L., Farrell N. Comparison of cytotoxicity and cellular accumulation of polynuclear platinum complexes in L1210 murine leukemia cell lines. J Inorg Biochem 1999, 77:47-50.
14. Servidei T., Ferlini C., Riccardi A., Meco D., Scambia G., Segni G., et al. The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin. Eur J Cancer 2001, 37:930-938.
15. Farrell N. Polynuclear charged platinum compounds as a new class of anticancer agents: toward a new paradigm. Platinum-based drugs in cancer therapy 2000, 321-338. Humana Press, Inc., Totowa, NJ. L.R. Kelland, N.P. Farrell (Eds.).
16. Harris A.L., Yang X., Hegmans A., Povirk L., Ryan J.J., Kelland L., et al. Synthesis, characterization, and cytotoxicity of a novel highly charged trinuclear platinum compound: enhancement of cellular uptake with charge. Inorg Chem 2005, 44:9598-9600.
17. Farrell N., Qu Y., Feng L., Van Houten B. Comparison of chemical reactivity, cytotoxicity, interstrand cross-linking and DNA sequence specificity of bis(platinum) complexes containing monodentate or bidentate coordination spheres with their monomeric analogues. Biochemistry 1990, 29:9522-9531.
18. Summa N., Maigut J., Puchta R., van Eldik R. Possible biotransformation reactions of polynuclear Pt(II) complexes. Inorg Chem 2007, 46:2094-2104.
19. 195Pt) NMR spectroscopy. Inorg Chem 2003, 42:5498-5506.
20. Billecke C., Finniss S., Tahash L., Miller C., Mikkelsen T., Farrell N.P., et al. Polynuclear platinum anticancer drugs are more potent than cisplatin and induce cell cycle arrest in glioma. Neuro Oncol 2006, 8:215-226.
21. Mitchell C., Kabolizadeh P., Ryan J., Roberts J.D., Yacoub A., Curiel D.T., et al. Low-dose BBR3610 toxicity in colon cancer cells is p53-independent and enhanced by inhibition of epidermal growth factor receptor (ERBB1)-phosphatidyl inositol 3 kinase signaling. Mol Pharmacol 2007, 72:704-714.
22. Williams J.W., Qu Y., Bulluss G.H., Alvorado E., Farrell N.P. Dinuclear platinum complexes with biological relevance based on the 1,2-diaminocyclohexane carrier ligand. Inorg Chem 2007, 46:5820-5822.
23. Fan D., Yang X., Wang X., Zhang S., Mao J., Ding J., et al. A dinuclear monofunctional platinum(II) complex with an aromatic linker shows low reactivity towards glutathione but high DNA binding ability and antitumor activity. J Biol Inorg Chem 2007, 12:655-665.
24. Jamieson E.R., Lippard S.J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 1999, 99:2467-2498.
25. Jung Y., Lippard S.J. Direct cellular responses to platinum-induced DNA damage. Chem Rev 2007, 107:1387-1407.
26. Brabec V., Kasparkova J. Role of DNA repair in antitumor effects of platinum drugs. Metal complex - DNA interactions 2009, 175-208. Wiley, Chichester, UK. N. Hadjiliadis, E. Sletten (Eds.).
27. Zhu J., Lin M., Fan D., Wu Z., Zhang J., Luc Y., et al. The role of bridging ligands in determining DNA-binding ability and cross-linking patterns of dinuclear platinum(II) antitumor complexes. Dalton Trans 2009, 10889-10895.
28. Brabec V., Palecek E. The influence of salts and pH on polarographic currents produced by denatured DNA. Biophysik 1970, 6:290-300.
29. Brabec V., Palecek E. Interaction of nucleic acids with electrically charged surfaces: II. Conformational changes in double-helical polynucleotides. Biophys Chem 1976, 4:76-92.
30. Kasparkova J., Delalande O., Stros M., Elizondo-Riojas M.A., Vojtiskova M., Kozelka J., et al. Recognition of DNA interstrand cross-link of antitumor cisplatin by HMGB1 protein. Biochemistry 2003, 42:1234-1244.
31. Stros M. DNA bending by the chromosomal protein HMG1 and its high mobility group box domains: effect of flanking sequences. J Biol Chem 1998, 273:10355-10361.
32. Stros M. Two mutations of basic residues within the N-terminus of HMG-1 B domain with different effects on DNA supercoiling and binding to bent DNA. Biochemistry 2001, 40:4769-4779.
33. Reardon J.T., Vaisman A., Chaney S.G., Sancar A. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 1999, 59:3968-3971.
34. Manley J.L., Fire A., Cano A., Sharp P.A., Gefter M.L. DNA-dependent transcription of adenovirus genes in a soluble whole-cell extract. Proc Natl Acad Sci USA 1980, 77:3855-3859.
35. Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988, 48:589-601.
36. Kim S.D., Vrana O., Kleinwächter V., Niki K., Brabec V. Polarographic determination of subnanogram quantities of free platinum in reaction mixture with DNA. Anal Lett 1990, 23:1505-1518.
37. 195Pt NMR kinetic and mechanistic studies of cis-diamminedichloroplatinum and trans-diamminedichloroplatinum(II) binding to DNA. J Am Chem Soc 1990, 112:6860-6871.
38. Brabec V., Leng M. DNA interstrand cross-links of trans-diamminedichloroplatinum(II) are preferentially formed between guanine and complementary cytosine residues. Proc Natl Acad Sci USA 1993, 90:5345-5349.
39. Brabec V. DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair. Prog Nucleic Acid Res Mol Biol 2002, 71:1-68.
40. Cohen S.M., Lippard S.J. Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol 2001, 67:93-130.
41. Jung Y.W., Lippard S.J. Nature of full-length HMGB1 binding to cisplatin-modified DNA. Biochemistry 2003, 42:2664-2671.
42. Huang J.C., Zamble D.B., Reardon J.T., Lippard S.J., Sancar A. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci USA 1994, 91:10394-10398.
43. Chau K.Y., Lam H.Y.P., Lee K.L.D. Estrogen treatment induces elevated expression of HMG1 in MCF-7 cells. Exp Cell Res 1998, 241:269-272.
44. He Q., Liang C.H., Lippard S.J. Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc Natl Acad Sci USA 2000, 97:5768-5772.
45. Brabec V., Kasparkova J. Molecular aspects of resistance to antitumor platinum drugs. Drug Resist Updat 2002, 5:147-161.
46. Hegmans A., Berners-Price S.J., Davies M.S., Thomas D., Humphreys A., Farrell N. Long range 1,4 and 1,6-interstrand cross-links formed by a trinuclear platinum complex: minor groove pre-association affects kinetics and mechanism of cross-link formation as well as adduct structure. J Am Chem Soc 2004, 126:2166-2180.
47. Berners-Price S.J., Davies M.S., Cox J.W., Thomas D.S., Farrell N. Competitive reactions of interstrand and intrastrand DNA-Pt adducts: a dinuclear-platinum complex preferentially forms a 1,4-interstrand cross-link rather than a 1,2 intrastrand cross-link on binding to a GG 14-Mer duplex. Chem Eur J 2003, 9:713-725.
48. Thomas J.O. HMG 1 and 2: architectural DNA-binding proteins. Biochem Soc Trans 2001, 29:395-401.
49. Comess K.M., Burstyn J.N., Essigmann J.M., Lippard S.J. Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-diamminedichloroplatinum(II) DNA adducts. Biochemistry 1992, 31:3975-3990.
50. Zamble D.B., Mu D., Reardon J.T., Sancar A., Lippard S.J. Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry 1996, 35:10004-10013.
51. Zhai X.Q., Beckmann H., Jantzen H.M., Essigmann J.M. Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor. Biochemistry 1998, 37:16307-16315.
52. Vichi P., Coin F., Renaud J.P., Vermeulen W., Hoeijmakers J.H.J., Moras D., et al. Cisplatin- and UV-damaged DNA lure the basal transcription factor TFIID/TBP. EMBO J 1997, 16:7444-7456.
53. Fichtinger-Schepman A.M.J., Van der Veer J.L., Den Hartog J.H.J., Lohman P.H.M., Reedijk J. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry 1985, 24:707-713.
54. Keck M.V., Lippard S.J. Unwinding of supercoiled DNA by platinum ethidium and related complexes. J Am Chem Soc 1992, 114:3386-3390.